Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication

Background A novel regimen with high‐dose dual therapy (HDDT) has emerged, but its impact on the gut microbiota is not well understood. This study aimed to evaluate the impact of HDDT on the gut microbiota and compare it with that of bismuth quadruple therapy (BQT). Methods We enrolled outpatients (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Helicobacter (Cambridge, Mass.) Mass.), 2024-03, Vol.29 (2), p.e13077-n/a
Hauptverfasser: Chen, Jing, Zhang, Yan, Min, Hanchen, Zhi, Junli, Ma, Shuyun, Dong, Hongxia, Yan, Jingshuang, Chi, Xiaoyan, Zhang, Xiaomei, Yang, Yunsheng
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 2
container_start_page e13077
container_title Helicobacter (Cambridge, Mass.)
container_volume 29
creator Chen, Jing
Zhang, Yan
Min, Hanchen
Zhi, Junli
Ma, Shuyun
Dong, Hongxia
Yan, Jingshuang
Chi, Xiaoyan
Zhang, Xiaomei
Yang, Yunsheng
description Background A novel regimen with high‐dose dual therapy (HDDT) has emerged, but its impact on the gut microbiota is not well understood. This study aimed to evaluate the impact of HDDT on the gut microbiota and compare it with that of bismuth quadruple therapy (BQT). Methods We enrolled outpatients (18–70 years) diagnosed with Helicobacter pylori infection by either histology or a positive 13C‐urea breath test (13C‐UBT) and randomly assigned to either the BQT or HDDT group. Subjects consented to provide fecal samples which were collected at baseline, Week 2, and Week 14. Amplification of the V1 and V9 regions of the 16S rRNA was conducted followed by high‐throughput sequencing. Results Ultimately, 78 patients (41 patients in the HDDT group and 37 in the BQT group) were enrolled in this study. Eradication therapy significantly altered the diversity of the gut microbiota. However, the alpha diversity rebounded only in the HDDT group at 12 weeks post‐eradication. Immediately following eradication, the predominance of Proteobacteria, replacing commensal Firmicutes and Bacteroidetes, did not recover after 12 weeks. Species‐level analysis showed that the relative abundances of Klebsiella pneumoniae and Escherichia fergusonii significantly increased in both groups at Week 2. Enterococcus faecium and Enterococcus faecalis significantly increased in the BQT group, with no significant difference observed in the HDDT group. After 12 weeks of treatment, the relative abundance of more species in the HDDT group returned to baseline levels. Conclusion Eradication of H. pylori can lead to an imbalance in gut microbiota. Compared to BQT, the HDDT is a regimen with milder impact on gut microbiota.
doi_str_mv 10.1111/hel.13077
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3048497949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3048497949</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3137-1e124598d2498bf99b19c94802ae098a8f9dd59a0fc992a6e1bc42af723ac3f3</originalsourceid><addsrcrecordid>eNp10b1u1TAYBmALgWgpDNwAssQCQ1r_5cQeUSkcpCOxdI--2M6JKydO7VgoGxMz18iV4ENKByS82PL36JXlF6HXlFzSsq4G6y8pJ03zBJ3TmvGq5o18Ws5E8kpwqc7Qi5TuCCE1F-o5OuNyJxnbyXP04-M6weg01gNMR5uwm_AyWHzMCy7XMXQuLIChX2zEnUtjXgZ8n8HEPHt7ohHmFcNk8OCOw6_vP01IFpsM_nHYh4j31jsdOtCnnHn1ITpcpsZpWFyYXqJnPfhkXz3sF-j2083t9b46fP385frDodKc8qailjJRK2mYULLrleqo0kpIwsASJUH2yphaAem1Ugx2lnZaMOgbxkHznl-gd1vsHMN9tmlpR5e09R4mG3JqORFSqEYJVejbf-hdyHEqj9sUaThnRb3fVPmplKLt2zm6EeLaUtKeumlLN-2fbop985CYu9GaR_m3jAKuNvDNebv-P6nd3xy2yN_hIpsg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3048407332</pqid></control><display><type>article</type><title>Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Chen, Jing ; Zhang, Yan ; Min, Hanchen ; Zhi, Junli ; Ma, Shuyun ; Dong, Hongxia ; Yan, Jingshuang ; Chi, Xiaoyan ; Zhang, Xiaomei ; Yang, Yunsheng</creator><creatorcontrib>Chen, Jing ; Zhang, Yan ; Min, Hanchen ; Zhi, Junli ; Ma, Shuyun ; Dong, Hongxia ; Yan, Jingshuang ; Chi, Xiaoyan ; Zhang, Xiaomei ; Yang, Yunsheng</creatorcontrib><description>Background A novel regimen with high‐dose dual therapy (HDDT) has emerged, but its impact on the gut microbiota is not well understood. This study aimed to evaluate the impact of HDDT on the gut microbiota and compare it with that of bismuth quadruple therapy (BQT). Methods We enrolled outpatients (18–70 years) diagnosed with Helicobacter pylori infection by either histology or a positive 13C‐urea breath test (13C‐UBT) and randomly assigned to either the BQT or HDDT group. Subjects consented to provide fecal samples which were collected at baseline, Week 2, and Week 14. Amplification of the V1 and V9 regions of the 16S rRNA was conducted followed by high‐throughput sequencing. Results Ultimately, 78 patients (41 patients in the HDDT group and 37 in the BQT group) were enrolled in this study. Eradication therapy significantly altered the diversity of the gut microbiota. However, the alpha diversity rebounded only in the HDDT group at 12 weeks post‐eradication. Immediately following eradication, the predominance of Proteobacteria, replacing commensal Firmicutes and Bacteroidetes, did not recover after 12 weeks. Species‐level analysis showed that the relative abundances of Klebsiella pneumoniae and Escherichia fergusonii significantly increased in both groups at Week 2. Enterococcus faecium and Enterococcus faecalis significantly increased in the BQT group, with no significant difference observed in the HDDT group. After 12 weeks of treatment, the relative abundance of more species in the HDDT group returned to baseline levels. Conclusion Eradication of H. pylori can lead to an imbalance in gut microbiota. Compared to BQT, the HDDT is a regimen with milder impact on gut microbiota.</description><identifier>ISSN: 1083-4389</identifier><identifier>EISSN: 1523-5378</identifier><identifier>DOI: 10.1111/hel.13077</identifier><identifier>PMID: 38682268</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>16S rRNA sequencing ; Adolescent ; Adult ; Aged ; Anti-Bacterial Agents - administration &amp; dosage ; Anti-Bacterial Agents - therapeutic use ; Bacteria - classification ; Bacteria - drug effects ; Bacteria - genetics ; Bacteria - isolation &amp; purification ; Bismuth ; Bismuth - administration &amp; dosage ; Bismuth - therapeutic use ; bismuth quadruple therapy ; Drug Therapy, Combination ; Eradication ; Feces ; Feces - microbiology ; Female ; Gastrointestinal Microbiome - drug effects ; gut microbiota ; Helicobacter Infections - drug therapy ; Helicobacter Infections - microbiology ; Helicobacter pylori ; Helicobacter pylori - drug effects ; Helicobacter pylori - physiology ; high‐dose dual therapy ; Histology ; Humans ; Intestinal microflora ; Klebsiella ; Male ; Microbiota ; Microorganisms ; Middle Aged ; Proton Pump Inhibitors - administration &amp; dosage ; Proton Pump Inhibitors - therapeutic use ; Relative abundance ; RNA, Ribosomal, 16S - genetics ; rRNA 16S ; Therapy ; Urea ; Young Adult</subject><ispartof>Helicobacter (Cambridge, Mass.), 2024-03, Vol.29 (2), p.e13077-n/a</ispartof><rights>2024 The Authors. published by John Wiley &amp; Sons Ltd.</rights><rights>2024 The Authors. Helicobacter published by John Wiley &amp; Sons Ltd.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3137-1e124598d2498bf99b19c94802ae098a8f9dd59a0fc992a6e1bc42af723ac3f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhel.13077$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhel.13077$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38682268$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Jing</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Min, Hanchen</creatorcontrib><creatorcontrib>Zhi, Junli</creatorcontrib><creatorcontrib>Ma, Shuyun</creatorcontrib><creatorcontrib>Dong, Hongxia</creatorcontrib><creatorcontrib>Yan, Jingshuang</creatorcontrib><creatorcontrib>Chi, Xiaoyan</creatorcontrib><creatorcontrib>Zhang, Xiaomei</creatorcontrib><creatorcontrib>Yang, Yunsheng</creatorcontrib><title>Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication</title><title>Helicobacter (Cambridge, Mass.)</title><addtitle>Helicobacter</addtitle><description>Background A novel regimen with high‐dose dual therapy (HDDT) has emerged, but its impact on the gut microbiota is not well understood. This study aimed to evaluate the impact of HDDT on the gut microbiota and compare it with that of bismuth quadruple therapy (BQT). Methods We enrolled outpatients (18–70 years) diagnosed with Helicobacter pylori infection by either histology or a positive 13C‐urea breath test (13C‐UBT) and randomly assigned to either the BQT or HDDT group. Subjects consented to provide fecal samples which were collected at baseline, Week 2, and Week 14. Amplification of the V1 and V9 regions of the 16S rRNA was conducted followed by high‐throughput sequencing. Results Ultimately, 78 patients (41 patients in the HDDT group and 37 in the BQT group) were enrolled in this study. Eradication therapy significantly altered the diversity of the gut microbiota. However, the alpha diversity rebounded only in the HDDT group at 12 weeks post‐eradication. Immediately following eradication, the predominance of Proteobacteria, replacing commensal Firmicutes and Bacteroidetes, did not recover after 12 weeks. Species‐level analysis showed that the relative abundances of Klebsiella pneumoniae and Escherichia fergusonii significantly increased in both groups at Week 2. Enterococcus faecium and Enterococcus faecalis significantly increased in the BQT group, with no significant difference observed in the HDDT group. After 12 weeks of treatment, the relative abundance of more species in the HDDT group returned to baseline levels. Conclusion Eradication of H. pylori can lead to an imbalance in gut microbiota. Compared to BQT, the HDDT is a regimen with milder impact on gut microbiota.</description><subject>16S rRNA sequencing</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bacteria - classification</subject><subject>Bacteria - drug effects</subject><subject>Bacteria - genetics</subject><subject>Bacteria - isolation &amp; purification</subject><subject>Bismuth</subject><subject>Bismuth - administration &amp; dosage</subject><subject>Bismuth - therapeutic use</subject><subject>bismuth quadruple therapy</subject><subject>Drug Therapy, Combination</subject><subject>Eradication</subject><subject>Feces</subject><subject>Feces - microbiology</subject><subject>Female</subject><subject>Gastrointestinal Microbiome - drug effects</subject><subject>gut microbiota</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter Infections - microbiology</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - drug effects</subject><subject>Helicobacter pylori - physiology</subject><subject>high‐dose dual therapy</subject><subject>Histology</subject><subject>Humans</subject><subject>Intestinal microflora</subject><subject>Klebsiella</subject><subject>Male</subject><subject>Microbiota</subject><subject>Microorganisms</subject><subject>Middle Aged</subject><subject>Proton Pump Inhibitors - administration &amp; dosage</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>Relative abundance</subject><subject>RNA, Ribosomal, 16S - genetics</subject><subject>rRNA 16S</subject><subject>Therapy</subject><subject>Urea</subject><subject>Young Adult</subject><issn>1083-4389</issn><issn>1523-5378</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp10b1u1TAYBmALgWgpDNwAssQCQ1r_5cQeUSkcpCOxdI--2M6JKydO7VgoGxMz18iV4ENKByS82PL36JXlF6HXlFzSsq4G6y8pJ03zBJ3TmvGq5o18Ws5E8kpwqc7Qi5TuCCE1F-o5OuNyJxnbyXP04-M6weg01gNMR5uwm_AyWHzMCy7XMXQuLIChX2zEnUtjXgZ8n8HEPHt7ohHmFcNk8OCOw6_vP01IFpsM_nHYh4j31jsdOtCnnHn1ITpcpsZpWFyYXqJnPfhkXz3sF-j2083t9b46fP385frDodKc8qailjJRK2mYULLrleqo0kpIwsASJUH2yphaAem1Ugx2lnZaMOgbxkHznl-gd1vsHMN9tmlpR5e09R4mG3JqORFSqEYJVejbf-hdyHEqj9sUaThnRb3fVPmplKLt2zm6EeLaUtKeumlLN-2fbop985CYu9GaR_m3jAKuNvDNebv-P6nd3xy2yN_hIpsg</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Chen, Jing</creator><creator>Zhang, Yan</creator><creator>Min, Hanchen</creator><creator>Zhi, Junli</creator><creator>Ma, Shuyun</creator><creator>Dong, Hongxia</creator><creator>Yan, Jingshuang</creator><creator>Chi, Xiaoyan</creator><creator>Zhang, Xiaomei</creator><creator>Yang, Yunsheng</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>202403</creationdate><title>Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication</title><author>Chen, Jing ; Zhang, Yan ; Min, Hanchen ; Zhi, Junli ; Ma, Shuyun ; Dong, Hongxia ; Yan, Jingshuang ; Chi, Xiaoyan ; Zhang, Xiaomei ; Yang, Yunsheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3137-1e124598d2498bf99b19c94802ae098a8f9dd59a0fc992a6e1bc42af723ac3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>16S rRNA sequencing</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bacteria - classification</topic><topic>Bacteria - drug effects</topic><topic>Bacteria - genetics</topic><topic>Bacteria - isolation &amp; purification</topic><topic>Bismuth</topic><topic>Bismuth - administration &amp; dosage</topic><topic>Bismuth - therapeutic use</topic><topic>bismuth quadruple therapy</topic><topic>Drug Therapy, Combination</topic><topic>Eradication</topic><topic>Feces</topic><topic>Feces - microbiology</topic><topic>Female</topic><topic>Gastrointestinal Microbiome - drug effects</topic><topic>gut microbiota</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter Infections - microbiology</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - drug effects</topic><topic>Helicobacter pylori - physiology</topic><topic>high‐dose dual therapy</topic><topic>Histology</topic><topic>Humans</topic><topic>Intestinal microflora</topic><topic>Klebsiella</topic><topic>Male</topic><topic>Microbiota</topic><topic>Microorganisms</topic><topic>Middle Aged</topic><topic>Proton Pump Inhibitors - administration &amp; dosage</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>Relative abundance</topic><topic>RNA, Ribosomal, 16S - genetics</topic><topic>rRNA 16S</topic><topic>Therapy</topic><topic>Urea</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Jing</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Min, Hanchen</creatorcontrib><creatorcontrib>Zhi, Junli</creatorcontrib><creatorcontrib>Ma, Shuyun</creatorcontrib><creatorcontrib>Dong, Hongxia</creatorcontrib><creatorcontrib>Yan, Jingshuang</creatorcontrib><creatorcontrib>Chi, Xiaoyan</creatorcontrib><creatorcontrib>Zhang, Xiaomei</creatorcontrib><creatorcontrib>Yang, Yunsheng</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Helicobacter (Cambridge, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Jing</au><au>Zhang, Yan</au><au>Min, Hanchen</au><au>Zhi, Junli</au><au>Ma, Shuyun</au><au>Dong, Hongxia</au><au>Yan, Jingshuang</au><au>Chi, Xiaoyan</au><au>Zhang, Xiaomei</au><au>Yang, Yunsheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication</atitle><jtitle>Helicobacter (Cambridge, Mass.)</jtitle><addtitle>Helicobacter</addtitle><date>2024-03</date><risdate>2024</risdate><volume>29</volume><issue>2</issue><spage>e13077</spage><epage>n/a</epage><pages>e13077-n/a</pages><issn>1083-4389</issn><eissn>1523-5378</eissn><abstract>Background A novel regimen with high‐dose dual therapy (HDDT) has emerged, but its impact on the gut microbiota is not well understood. This study aimed to evaluate the impact of HDDT on the gut microbiota and compare it with that of bismuth quadruple therapy (BQT). Methods We enrolled outpatients (18–70 years) diagnosed with Helicobacter pylori infection by either histology or a positive 13C‐urea breath test (13C‐UBT) and randomly assigned to either the BQT or HDDT group. Subjects consented to provide fecal samples which were collected at baseline, Week 2, and Week 14. Amplification of the V1 and V9 regions of the 16S rRNA was conducted followed by high‐throughput sequencing. Results Ultimately, 78 patients (41 patients in the HDDT group and 37 in the BQT group) were enrolled in this study. Eradication therapy significantly altered the diversity of the gut microbiota. However, the alpha diversity rebounded only in the HDDT group at 12 weeks post‐eradication. Immediately following eradication, the predominance of Proteobacteria, replacing commensal Firmicutes and Bacteroidetes, did not recover after 12 weeks. Species‐level analysis showed that the relative abundances of Klebsiella pneumoniae and Escherichia fergusonii significantly increased in both groups at Week 2. Enterococcus faecium and Enterococcus faecalis significantly increased in the BQT group, with no significant difference observed in the HDDT group. After 12 weeks of treatment, the relative abundance of more species in the HDDT group returned to baseline levels. Conclusion Eradication of H. pylori can lead to an imbalance in gut microbiota. Compared to BQT, the HDDT is a regimen with milder impact on gut microbiota.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38682268</pmid><doi>10.1111/hel.13077</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1083-4389
ispartof Helicobacter (Cambridge, Mass.), 2024-03, Vol.29 (2), p.e13077-n/a
issn 1083-4389
1523-5378
language eng
recordid cdi_proquest_miscellaneous_3048497949
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects 16S rRNA sequencing
Adolescent
Adult
Aged
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - therapeutic use
Bacteria - classification
Bacteria - drug effects
Bacteria - genetics
Bacteria - isolation & purification
Bismuth
Bismuth - administration & dosage
Bismuth - therapeutic use
bismuth quadruple therapy
Drug Therapy, Combination
Eradication
Feces
Feces - microbiology
Female
Gastrointestinal Microbiome - drug effects
gut microbiota
Helicobacter Infections - drug therapy
Helicobacter Infections - microbiology
Helicobacter pylori
Helicobacter pylori - drug effects
Helicobacter pylori - physiology
high‐dose dual therapy
Histology
Humans
Intestinal microflora
Klebsiella
Male
Microbiota
Microorganisms
Middle Aged
Proton Pump Inhibitors - administration & dosage
Proton Pump Inhibitors - therapeutic use
Relative abundance
RNA, Ribosomal, 16S - genetics
rRNA 16S
Therapy
Urea
Young Adult
title Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T04%3A58%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dynamic%20changes%20in%20the%20gut%20microbiota%20after%20bismuth%20quadruple%20therapy%20and%20high%E2%80%90dose%20dual%20therapy%20for%20Helicobacter%20pylori%20eradication&rft.jtitle=Helicobacter%20(Cambridge,%20Mass.)&rft.au=Chen,%20Jing&rft.date=2024-03&rft.volume=29&rft.issue=2&rft.spage=e13077&rft.epage=n/a&rft.pages=e13077-n/a&rft.issn=1083-4389&rft.eissn=1523-5378&rft_id=info:doi/10.1111/hel.13077&rft_dat=%3Cproquest_cross%3E3048497949%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3048407332&rft_id=info:pmid/38682268&rfr_iscdi=true